BACKGROUND: Renin-angiotensin system (RAS) blockers slow the progression of chronic kidney disease (CKD). Despite this, up to 40% of patients with CKD and an indication for RAS blockade do not receive these medications. The purpose of this study was to examine variables associated with the prescription of RAS blockers in patients with CKD and to identify opportunities to increase their use. METHODS: The electronic medical records of patients with moderate to severe CKD and an indication for RAS blockade were reviewed. For patients with an indication for RAS blockade who were not prescribed these medications, previous notes were reviewed to ascertain reasons why RAS blockade was not prescribed. RESULTS: Six hundred twenty-seven patients with moderate to severe CKD and an indication for RAS blockade were identified. Of these patients, 225 (36%) were not prescribed RAS blockade. This group was found to have significantly less diabetes, to be significantly older and to have significantly lower estimated glomerular filtration rate and blood pressure than the group on RAS blockade. For the majority (59%), no documented reason for not being prescribed RAS blockade was found. Among documented reasons, hyperkalemia and a history of acute kidney injury were the most common. CONCLUSIONS: The authors found that a large proportion of patients with CKD and an indication for RAS blockade were not prescribed these medications. For the majority, there was no provider-documented reason explaining why these medications were not prescribed, and the findings suggest that there may be opportunities to increase RAS blocker prescribing.
BACKGROUND:Renin-angiotensin system (RAS) blockers slow the progression of chronic kidney disease (CKD). Despite this, up to 40% of patients with CKD and an indication for RAS blockade do not receive these medications. The purpose of this study was to examine variables associated with the prescription of RAS blockers in patients with CKD and to identify opportunities to increase their use. METHODS: The electronic medical records of patients with moderate to severe CKD and an indication for RAS blockade were reviewed. For patients with an indication for RAS blockade who were not prescribed these medications, previous notes were reviewed to ascertain reasons why RAS blockade was not prescribed. RESULTS: Six hundred twenty-seven patients with moderate to severe CKD and an indication for RAS blockade were identified. Of these patients, 225 (36%) were not prescribed RAS blockade. This group was found to have significantly less diabetes, to be significantly older and to have significantly lower estimated glomerular filtration rate and blood pressure than the group on RAS blockade. For the majority (59%), no documented reason for not being prescribed RAS blockade was found. Among documented reasons, hyperkalemia and a history of acute kidney injury were the most common. CONCLUSIONS: The authors found that a large proportion of patients with CKD and an indication for RAS blockade were not prescribed these medications. For the majority, there was no provider-documented reason explaining why these medications were not prescribed, and the findings suggest that there may be opportunities to increase RAS blocker prescribing.
Authors: Gema Ruiz-Hurtado; Pantelis Sarafidis; María S Fernández-Alfonso; Bernard Waeber; Luis M Ruilope Journal: Nat Rev Cardiol Date: 2016-04-07 Impact factor: 32.419
Authors: Irene Capelli; Lorenzo Gasperoni; Marco Ruggeri; Gabriele Donati; Olga Baraldi; Giovanni Sorrenti; Maria Turchese Caletti; Valeria Aiello; Giuseppe Cianciolo; Gaetano La Manna Journal: J Nephrol Date: 2019-04-15 Impact factor: 3.902
Authors: Toshiaki Ohkuma; Katie Harris; Mark Cooper; Diederick E Grobbee; Pavel Hamet; Stephen Harrap; Giuseppe Mancia; Michel Marre; Anushka Patel; Anthony Rodgers; Bryan Williams; Mark Woodward; John Chalmers Journal: Clin J Am Soc Nephrol Date: 2022-07-27 Impact factor: 10.614
Authors: Mark Bounthavong; Javed Butler; Chantal M Dolan; Jeffrey D Dunn; Kathryn A Fisher; Nina Oestreicher; Bertram Pitt; Paul J Hauptman; David L Veenstra Journal: Pharmacoeconomics Date: 2018-12 Impact factor: 4.981
Authors: Eleonora Riccio; Ivana Capuano; Pasquale Buonanno; Michele Andreucci; Michele Provenzano; Maria Amicone; Manuela Rizzo; Antonio Pisani Journal: Front Cardiovasc Med Date: 2022-02-11
Authors: Ghassan Bandak; Yingying Sang; Alessandro Gasparini; Alex R Chang; Shoshana H Ballew; Marie Evans; Johan Arnlov; Lars H Lund; Lesley A Inker; Josef Coresh; Juan-Jesus Carrero; Morgan E Grams Journal: J Am Heart Assoc Date: 2017-07-19 Impact factor: 5.501